Perspective Therapeutics (CATX) AI Stock Analysis

• Market Cap: $142.18M
• Dividend Yield: N/A
• Average Volume (3M): 799.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.94
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 138
• Sector: Healthcare
• Sector Strength: 64
• Industry: Medical - Devices
• EPS (TTM): -1.21
• Shares Outstanding: 74,051,840
• 10 Day Avg. Volume: 1,065,940
• 30 Day Avg. Volume: 799,635
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 139.61
• Price to Cash Flow (P/CF): 12.70
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $13.82
• Price Target Upside: 545.79% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

Perspective Therapeutics is facing severe operational challenges with no revenue and increasing net losses, which significantly impact its financial performance score. While the company's balance sheet shows some strength due to low leverage, the reliance on external financing raises sustainability concerns. The technical analysis indicates ongoing downward pressure, and the negative P/E ratio reflects severe valuation concerns. Overall, the stock's prospects are weak, requiring strategic turnaround efforts to improve its outlook.

Positive Factors

Analyst Recommendation

Analyst's recommendation includes a Buy rating and a 12-month price target of $10.

Clinical Trials Progress

Enrollment in the ongoing Phase I/IIa trial of lead asset Pb-212-VMT-α-NET in SSTR2+ NETs has picked up with a total of 30 patients treated, indicating progress in clinical trials.

Financial Stability

Perspective ended 2024 with ~$227M in cash, cash equivalents, and marketable securities, which should provide a runway into late 2026.

Negative Factors

Clinical Trial Challenges

VMT01 Demonstrated Limited Monotherapy Activity in the First Two Cohorts.

Financial Performance

A net loss of $1.22 per share was reported for 2024, significantly wider than the prior estimated net loss of $0.32 per share.

Risks and Uncertainties

Risks include negative clinical results with the lead asset, delays in advancing pipeline candidates, inability to obtain regulatory approvals, competitive risks, and long-term dilution risk.

Perspective Therapeutics Business Overview & Revenue Model

Company Description

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.

How the Company Makes Money

Perspective Therapeutics makes money primarily through the commercialization of its proprietary therapeutic solutions. The company generates revenue by licensing its technologies to pharmaceutical companies, receiving milestone payments and royalties from successful product developments. Additionally, Perspective Therapeutics may engage in strategic partnerships and collaborations with other biotech firms and research institutions to co-develop products, further expanding its revenue streams. The company may also earn income from government grants and subsidies aimed at fostering innovation in healthcare.

Perspective Therapeutics Financial Statement Overview

Summary

Perspective Therapeutics faces significant financial challenges, with declining revenues and persistent losses affecting profitability. Despite these issues, the company maintains a strong balance sheet with high equity and low debt, offering financial stability. However, cash flow inefficiencies highlight operational challenges that need addressing to improve overall financial health and performance.

Income Statement

Perspective Therapeutics is experiencing significant revenue decline in the TTM period, with a notable drop from $1,434,000 in 2023 to $337,000. The company has a negative EBIT and EBITDA margin, reflecting operational inefficiencies. The net profit margin is negative due to high net losses, indicating a challenging profitability scenario. Overall, the financial health in terms of income is weak, with a downward trajectory in revenue and profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 84% and low debt levels, resulting in a favorable debt-to-equity ratio of 0.01. This indicates financial stability despite operational losses. However, the return on equity is negative due to net losses, reflecting poor profitability against the sizable equity base.

Cash Flow

Cash flow management is mixed, with a negative operating cash flow indicating operational cash generation issues. Free cash flow is also negative, reflecting high capital expenditures. The operating cash flow to net income ratio is unfavorable, showing inefficiencies in converting profit to cash. However, financing activities have bolstered cash reserves, providing some liquidity.

Breakdown
TTM	Dec 2023	Dec 2022	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
337.00K	1.43M	7.10M	10.79M	10.05M	9.68M
	Gross Profit
337.00K	1.43M	1.63M	4.62M	5.12M	5.12M
	EBIT
-53.71M	-40.94M	-15.18M	-7.39M	-3.44M	-3.48M
	EBITDA
-45.09M	-39.96M	-14.84M	-7.39M	-3.43M	-3.48M
	Net Income Common Stockholders
-63.78M	-46.51M	-14.67M	-7.15M	-3.19M	-3.27M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.87M	9.24M	43.76M	55.89M	63.83M	2.39M
	Total Assets
11.91M	97.89M	58.09M	64.44M	70.42M	8.70M
	Total Debt
0.00	2.55M	0.00	524.00K	776.00K	1.00M
	Net Debt
-3.20M	-6.69M	-20.99M	-55.37M	-63.05M	-1.39M
	Total Liabilities
2.25M	22.71M	3.45M	3.16M	3.01M	2.98M
	Stockholders Equity
9.66M	75.18M	54.64M	61.28M	67.41M	5.72M
Cash Flow		Free Cash Flow
-40.59M	-37.98M	-12.47M	-7.98M	-3.22M	-3.91M
	Operating Cash Flow
-696.00K	-36.91M	-12.17M	-7.71M	-2.84M	-3.64M
	Investing Cash Flow
-80.42M	24.37M	-57.68M	-284.00K	-410.00K	-287.00K
	Financing Cash Flow
289.39M	785.00K	56.00K	56.00K	64.68M	994.00K

Perspective Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.14
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CATX, the sentiment is Neutral. The current price of 2.14 is above the 20-day moving average (MA) of 2.02, below the 50-day MA of 2.43, and below the 200-day MA of 7.75, indicating a neutral trend. The MACD of -0.14 indicates Negative momentum. The RSI at 49.60 is Neutral, neither overbought nor oversold. The STOCH value of 75.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CATX.

Perspective Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LNSR	70 Neutral	$162.59M	―	-95.42%	―	26.87%	-104.94%
BWAY	67 Neutral	$156.16M	51.35	5.62%	―	29.04%	―
MASS	57 Neutral	$169.58M	―	-51.56%	―	18.72%	-86.45%
MYO	51 Neutral	$147.15M	―	-36.69%	―	69.17%	39.01%
Sector *	51 Neutral	$5.20B	3.18	-40.80%	2.96%	17.66%	1.94%
CVRX	50 Neutral	$157.78M	―	-81.58%	―	30.53%	-35.97%
CATX	41 Neutral	$142.18M	―	-19.42%	―	―	―

Perspective Therapeutics Corporate Events

Perspective Therapeutics Appoints New Chief Financial Officer

Perspective Therapeutics has appointed Juan Graham as the new Chief Financial Officer, succeeding Jonathan Hunt who remains as Chief Accounting Officer. With nearly 25 years of experience in biopharmaceutical financial management, Graham’s expertise is expected to enhance the company’s strategic financial operations and support its growth, particularly as it advances its clinical programs and builds manufacturing infrastructure.